An experimental, oral medicine originally developed by PTC Therapeutics and now licensed to Roche improved the muscle function of babies with a fatal form of the rare, genetic disease known as spinal muscular atrophy, according to preliminary results from a clinical trial presented Saturday.

More testing needs to be done to confirm these findings, but if they hold up, the new drug from PTC and Roche could be a significant competitive threat to Spinraza, the first chronic drug approved to treat SMA patients, marketed by Biogen.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy